# US 2025/0367155 A1 · Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367155 A1
- Document ID: US20250367155A1
- Status: Published application
- Kind: A1
- Application number: 19/300,233
- Filed: 2025-08-14
- Published: 2025-12-04
- Earliest claimed: 2021-01-14
- Inventors: Rob D. Dickerman
- Web page: https://patentgrep.com/patent/US20250367155A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods are presented that, upon administration prior to trauma, are effective to prevent and/or reduce severity of sequelae of TBI upon trauma. Advantageously, the compositions presented herein can be orally administered, have an excellent safety profile, and will not require a prescription by physician or hospital admission. Further contemplated compositions and methods are presented to be effective to prevent and/or reduce severity of sequelae of glutamate excitotoxicity.

## Claims

### Claim 1

A pharmaceutically acceptable composition for neuroprotection against glutamate excitotoxicity, comprising:
i) a branched chain amino acid (BCAA) component comprising leucine, valine, and isoleucine, wherein the leucine, valine, and isoleucine are present at a weight ratio of X:1:1, with X being between 2-4; and
ii) a vitamin component comprising vitamin B7 and at least one vitamin selected from the group consisting of vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B9, and vitamin B12;
wherein the composition is formulated for intravenous administration and is effective in preventing or reducing sequelae of the glutamate excitotoxicity.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the glutamate excitotoxicity is induced by traumatic brain injury, anoxic brain injury, paroxysmal sympathetic hyperactivity, cerebral inflammation, autonomic dysfunction, ischemia, seizure, stroke, epilepsy, neurodegenerative diseases, or prolonged hospitalization.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the leucine, the valine, and the isoleucine are present in the composition in a total amount of 8,550 mg (+/−10%) per dosage unit.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the leucine, the valine, and the isoleucine are present in the composition in a total amount of between 7,550 mg and 14,600 mg (+/−10%) per dosage unit.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the vitamin B7 is present in an amount of between 3-150 mg per dosage unit.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the vitamin C is present in an amount of between 50-500 mg, the vitamin B3 is present in an amount of between 5-50 mg, the vitamin B5 is present in an amount of between 0.5-25 mg, vitamin B6 is present in an amount of between 1-50 mg, vitamin B9 is present in an amount of between 80-1,000 mcg, and vitamin B12 is present in an amount of between 5-250 mcg per dosage unit.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition further comprises one or more minerals, a carbohydrate, and/or an herbal extract or component thereof.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the dosage unit is formulated as a fluid for injection as a single bolus or for infusion over a set period.

### Claim 9

A method of providing neuroprotection to prevent or reduce sequelae of glutamate excitotoxicity in a subject, the method comprising:
administering to the subject an intravenous pharmaceutical composition comprising:
i) a branched chain amino acid (BCAA) component comprising leucine, valine, and isoleucine, wherein the leucine, valine, and isoleucine are present at a weight ratio of X:1:1, with X being between 2-4; and
ii) a vitamin component comprising vitamin B7 and at least one vitamin selected from the group consisting of vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B9, and vitamin B12
wherein the administration of the composition prevents or reduces sequelae associated with glutamate excitotoxicity.

### Claim 10 (depends on 9)

The method of claim 9, wherein the sequelae of glutamate excitotoxicity is induced by traumatic brain injury, anoxic brain injury, paroxysmal sympathetic hyperactivity, cerebral inflammation, autonomic dysfunction, ischemia, seizure, stroke, epilepsy, neurodegenerative diseases, or prolonged hospitalization.

### Claim 11 (depends on 9)

The method of claim 9, wherein the BCAA component is present in the composition in an amount of 10,000 mg +/−10%.

### Claim 12 (depends on 9)

The method of claim 9, wherein the leucine, the valine, and the isoleucine are present in the composition in a total amount of 8,550 mg (+/−10%) per dosage unit.

### Claim 13 (depends on 9)

The method of claim 9, wherein the leucine, the valine, and the isoleucine are present in the composition in a total amount of between 7,550 mg and 14,600 mg (+/−10%) per dosage unit.

### Claim 14 (depends on 9)

The method of claim 9, wherein the vitamin B7 is present in an amount of between 3-150 mg per dosage unit.

### Claim 15 (depends on 9)

The method of claim 9, wherein the vitamin C is present in an amount of between 50-500 mg, the vitamin B3 is present in an amount of between 5-50 mg, the vitamin B5 is present in an amount of between 0.5-25 mg, vitamin B6 is present in an amount of between 1-50 mg, vitamin B9 is present in an amount of between 80-1,000 mcg, and vitamin B12 is present in an amount of between 5-250 mcg per dosage unit.

### Claim 16 (depends on 9)

The method of claim 9, wherein administration of the composition may further comprise administration of one or more minerals, a carbohydrate, and/or an herbal extract or component thereof.

### Claim 17 (depends on 9)

The method of claim 9, wherein the dosage unit is formulated as a fluid for injection as a single bolus or for infusion over a set period.

### Claim 18 (depends on 9)

The method of claim 9, wherein the composition in finished dosage form is selected from the group comprising an oral suspension, syringe, ampoule, vial, or infusion bag.

### Claim 19 (depends on 9)

The method of claim 9, wherein the step of administering the composition comprises injection as a single bolus or infusion over a set period.

### Claim 20 (depends on 9)

The method of claim 9, further comprising monitoring the subject and administering the dosage unit for the duration of hospitalization.
